
Report Explores Future of Opioid Abuse-Resistant Formulations
A GBI Research report says the opioid market will be driven by development of new products and post-marketing studies designed to reduce abuse risk.
A new
Many companies are working to develop abuse-resistant formulations of extended-release (ER) opioid analgesics, notes GBI Research. Most recent marketing approvals for ER opioids in the US have included risk evaluation and mitigation strategies that require license holders to provide physician training and raise patient awareness of opioid abuse. In many cases, post-marketing studies are required to examine the efficacy of abuse-resistant formulations. Initial post-marketing data reports for Embeda, which was launched in the US in 2009, are positive.
The current opioids market has a broad and highly diversified product profile, reports GBI Research. The developmental pipeline is small, however, and the market is relatively stagnant. Competition among abuse-resistant products is expected to be the driving factor in this market.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.